Wenjun Cai

Wenjun Cai

Auto-generated profile, based on publicly available information

Wenjun Cai

Department of Pain Management, Center for Rehabilitation Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in In Vitro Cellular & Developmental Biology - Animal
Verified
Journal Article
Open access
PDF file
LXLanghai Xu
Langhai Xu
ZCZhonggai Chen
Zhonggai Chen
TGTingting Geng
Tingting Geng
BRBin Ru
Bin Ru
QWQuan Wan
Quan Wan
WCWenjun Cai
Wenjun Cai
Tendinopathy is a common tendon disorder characterized by pain, swelling, and dysfunction. Current evidence has demonstrated that the depletion of stem cell pool and non-tenogenic differentiation of tendon-derived stem/progenitor cells (TSPCs) might account for the pathogenesis of tendinopathy. FNDC5/Irisin, as a novel exercise-induced myokine, is proved to be involved in the exercise-induced protective effects on musculoskeletal disorders. However, whether irisin can affect TSPCs fate is still unknown. To ascertain the roles of irisin on the proliferation and tenogenic differentiation of TSPCs, rat TSPCs were isolated and incubated with irisin. Cell viability, phenotypic changes, and related signaling pathways were evaluated by CCK-8 assay, colony formation assay, real-time PCR, Western blot, immunofluorescence, and proteasome activity assay. We found that irisin treatment increased the proliferative and colony-forming abilities, and promoted the tenogenic differentiation of TSPCs by upregulating the expression of YAP/TAZ. In conclusion, our work showed for the first time that irisin promotes the proliferation and tenogenic differentiation of rat TSPCs in vitro by activating YAP/TAZ, and the process was associated with a ubiquitin-proteasome proteolytic pathway. In conclusion, irisin and agents targeting YAP/TAZ may be promising therapeutic options for tendinopathy.


19 September 2024 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
YXYun Xu
Yun Xu
YLYang Liu
Yang Liu
DDDing Ding
Ding Ding
BRBin Ru
Bin Ru
QWQuan Wan
Quan Wan
WCWenjun Cai
Wenjun Cai
Objective: To assess the clinical impact of unilateral laminotomy for bilateral decompression (ULBD) in managing patients with adjacent vertebrae following lumbar fusion.Methods: A retrospective analysis was conducted on 21 patients, with a mean age of 67.4 years, who underwent ULBD for adjacent vertebra disease at our department from January 2021 to November 2023. We reviewed demographic data, surgical techniques, imaging studies, and patient-reported outcomes. The study compared Visual Analog Scale (VAS) scores, Numeric Rating Scale (NRS) scores, Japanese Orthopaedic Association (JOA) scores, Short Form-36 (SF-36) scores, and imaging outcomes before surgery, immediately post-surgery, and at 1 month, 6 months, and 12 months post-surgery.Results: Evaluation of 21 patients with adjacent segment disease (ASD) (13 males, 8 females; mean age 67.42 years) was performed with follow-ups at various intervals post-surgery. Postoperative VAS, NRS, JOA, and SF-36 scores showed significant improvements compared to preoperative scores. Immediately after surgery, there were significant improvements in NRS score (2.76 ± 0.70 vs. 3.71 ± 0.85, P < 0.05) and JOA score (15.38 ± 1.02 vs. 9.29 ± 1.01, P < 0.05) compared to preoperative scores. Similarly, at 12 months post-surgery, significant improvements were observed in NRS score (1.52 ± 0.51 vs. 3.71 ± 0.85, P < 0.05) and JOA score (25.0 ± 1.10 vs. 9.29 ± 1.01, P < 0.05) compared to preoperative scores. The clinical satisfaction rate was 95.0% among all patients, with postoperative imaging examinations revealing a significant decompression effect. No complications were reported among the surgical patients.Conclusions: This study suggests that endoscopic ULBD can be a safe and effective technique for managing symptomatic ASD, providing satisfactory clinical outcomes for patients with ASD. Endoscopic ULBD may serve as an alternative treatment option for ASD with lumbar stenosis.

30 January 2024
Verified
Preprint
Open access
PDF file
BRBin Ru
Bin Ru
ZCZhonggai Chen
Zhonggai Chen
LXLanghai Xu
Langhai Xu
SLShun Li
Shun Li
WCWenjun Cai
Wenjun Cai
Background Extracellular matrix (ECM) degradation, chondrocyte inflammation, and cellular senescence contribute to the pathology of osteoarthritis (OA). Empagliflozin, a selective inhibitor of sodium-glucose cotransporter-2 (SGLT2), has been reported to show the anti-inflammatory properties in several conditions. However, whether empagliflozin can be used to improve OA is still unknown. Methods The protective effects and underlying mechanism of empagliflozin in OA were investigated in vitro and in vivo. Cell viability, catabolic markers, inflammatory mediators, cellular senescence level, cartilage degeneration were evaluated by CCK-8 assay, safranine O staining, ELISA, real-time PCR, western blot, β-galactosidase Staining, and histological analysis. Results We found that empagliflozin significantly downregulated the expression of catabolic enzymes (MMP9 and MMP13), and decreased the expression of inflammatory mediators (NO, PGE2, IL-6, COX2, and INOS), and reduced the cellular senescence level in IL-1β-treated chondrocytes by inhibiting the nuclear factor kappa-B (NF-κB) signaling pathway. What’s more, empagliflozin prevented cartilage degeneration in DMM-induced OA mice model with significant lower OARSI grade. Conclusion Our findings reveal that empagliflozin inhibited chondrocytes ECM degradation, inflammation and cellular senescence in vitro and prevented cartilage degeneration in vivo by suppressing NF-κB signal pathway, indicating a therapeutic potential in OA treatment.

29 October 2024 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
YXYun Xu
Yun Xu
YLYang Liu
Yang Liu
DDDing Ding
Ding Ding
BRBin Ru
Bin Ru
QWQuan Wan
Quan Wan
WCWenjun Cai
Wenjun Cai
• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.